Armed With A Range Of Insulins, Pfizer Is Weeks Away From Its First Biosimilar Rollout In India - BIO 2011 Conference
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is counting on a set of value propositions, high quality and competitive pricing to emerge as a "natural leader" in the Indian market.